JAGSONPAL PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of JAGSONPAL PHARMACEUTICALS have decreased by -11.83% YoY .
The Earnings Per Share (EPS) of JAGSONPAL PHARMACEUTICALS has decreased by -1.88 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
JAGSONPAL PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 507789|NSE : JAGSNPHARM]
| Standalone | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹209 Cr | ₹237 Cr | ₹218 Cr | ₹1,879 Cr | ₹159 Cr |
| Expenses | ₹186 Cr | ₹203 Cr | ₹193 Cr | ₹1,689 Cr | ₹150 Cr |
| Operating Profit (Excl OI) | ₹23 Cr | ₹34 Cr | ₹25 Cr | ₹191 Cr | ₹8.53 Cr |
| Other Income | ₹9.28 Cr | ₹5.73 Cr | ₹3.43 Cr | ₹44 Cr | ₹2.53 Cr |
| Interest | ₹0.81 Cr | ₹0.41 Cr | ₹0.29 Cr | ₹5.14 Cr | ₹0.51 Cr |
| Depreciation | ₹1.66 Cr | ₹1.21 Cr | ₹1.53 Cr | ₹11 Cr | ₹1.13 Cr |
| Profit Before Tax | ₹30 Cr | ₹35 Cr | ₹27 Cr | ₹219 Cr | ₹9.42 Cr |
| Profit After Tax | ₹22 Cr | ₹27 Cr | ₹19 Cr | ₹171 Cr | ₹7.87 Cr |
| Earnings Per Share (Rs) | ₹8.34 | ₹8.50 | ₹10.20 | ₹7.20 | ₹6.51 |
| PAT Margin (%) | 19.65 | 10.01 | 10.39 | 7.78 | 9.08 |
| ROE(%) | 28.51 | 14.02 | 18.89 | 15.28 | 15.70 |
| ROCE(%) | 33.14 | 17.72 | 24.15 | 21.23 | 19.43 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 |
Key Financials |
||
| Market Cap | : | ₹ 1,439.5 Cr |
| Revenue (TTM) | : | ₹ 282.7 Cr |
| Net Profit(TTM) | : | ₹ 61.9 Cr |
| EPS (TTM) | : | ₹ 9.3 |
| P/E (TTM) | : | 23.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| JAGSONPAL PHARMACEUTICALS | 7.9% | -3.2% | -26.9% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.8% | 6.7% | 2.8% |
| DIVIS LABORATORIES | 1.9% | -0.5% | 6.9% |
| CIPLA | 1.8% | -3.2% | 2.1% |
| TORRENT PHARMACEUTICALS | 0.1% | 3.4% | 15.8% |
| DR REDDYS LABORATORIES | 2.7% | 0.4% | 3.4% |
| MANKIND PHARMA | 1.4% | -7.9% | -13% |
| ZYDUS LIFESCIENCES | 1.7% | -5.9% | -1.6% |
| LUPIN | 4.1% | 6.4% | 1.8% |
JAGSONPAL PHARMACEUTICALS Revenues
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | -11.83 % |
| 5 Yr CAGR | 7.11 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹209 Cr | -11.83 | |
| Mar2024 | ₹237 Cr | 8.79 | |
| Mar2023 | ₹218 Cr | -88.42 | |
| Mar2022 | ₹1,879 Cr | 1,085.27 | |
| Mar2021 | ₹159 Cr | - | |
JAGSONPAL PHARMACEUTICALS Operating Profit
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | -32.46 % |
| 5 Yr CAGR | 28.22 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹23 Cr | -32.46 | |
| Mar2024 | ₹34 Cr | 36.47 | |
| Mar2023 | ₹25 Cr | -86.88 | |
| Mar2022 | ₹191 Cr | 2,135.85 | |
| Mar2021 | ₹8.53 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -23.42 % |
| 5 Yr CAGR | 19.71 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 11.05% | -23.42 | |
| Mar2024 | 14.43% | 25.48 | |
| Mar2023 | 11.5% | 13.30 | |
| Mar2022 | 10.15% | 88.66 | |
| Mar2021 | 5.38% | - | |
JAGSONPAL PHARMACEUTICALS Profit After Tax
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | -15.94 % |
| 5 Yr CAGR | 29.97 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹22 Cr | -15.94 | |
| Mar2024 | ₹27 Cr | 41.72 | |
| Mar2023 | ₹19 Cr | -88.95 | |
| Mar2022 | ₹171 Cr | 2,067.23 | |
| Mar2021 | ₹7.87 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 96.30 % |
| 5 Yr CAGR | 21.29 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 19.65 % | 96.30 | |
| Mar2024 | 10.01 % | -3.66 | |
| Mar2023 | 10.39 % | 33.55 | |
| Mar2022 | 7.78 % | -14.32 | |
| Mar2021 | 9.08 % | - | |
JAGSONPAL PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | -1.88 % |
| 5 Yr CAGR | 6.39 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹8.34 | -1.88 | |
| Mar2024 | ₹8.50 | -16.67 | |
| Mar2023 | ₹10 | 41.67 | |
| Mar2022 | ₹7.20 | 10.60 | |
| Mar2021 | ₹6.51 | - | |
JAGSONPAL PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 507789|NSE : JAGSNPHARM]
| Y-o-Y | 87.02 % |
| 5 Yr CAGR | 14.28 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 33.14% | 87.02 | |
| Mar2024 | 17.72% | -26.63 | |
| Mar2023 | 24.15% | 13.75 | |
| Mar2022 | 21.23% | 9.26 | |
| Mar2021 | 19.43% | - | |
JAGSONPAL PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹215.5 |
| Current MarketCap | : | ₹ 1,439.5 Cr |
| Updated EOD on | : | Nov 28,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| JAGSONPAL PHARMACEUTICALS | 7.9% |
-3.2% |
-26.9% |
| SENSEX | 0.6% |
1.3% |
7% |
JAGSONPAL PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE HEALTHCARE | 1.1% | 0.2% | 3.5% |
| BSE SMALLCAP | 0.1% | -3.3% | -2.9% |
No NSE index found
You may also like the below Video Courses
FAQ about JAGSONPAL PHARMACEUTICALS Financials
How the annual revenues of JAGSONPAL PHARMACEUTICALS have changed ?
The Revenues of JAGSONPAL PHARMACEUTICALS have decreased by -11.83% YoY .
How the Earnings per Share (EPS) of JAGSONPAL PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of JAGSONPAL PHARMACEUTICALS has decreased by -1.88 % YoY .
Check out Intrinsic Value of Peers of JAGSONPAL PHARMACEUTICALS
Compare Stock Analytics of Peers of JAGSONPAL PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
